Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Ruxolitinib for Previously Enrolled Subjects
NCT02955940Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Nov 2016
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ruxolitinib in pancreatic cancer (PC), colorectal cancer (CRC), breast cancer and 1 more (3 arms), sponsored by Incyte. Primary endpoint: Frequency and types of adverse events and serious adverse events up to 24 months. Started Nov 2016; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)breast cancerlung cancer
Beyond the preview
Go deeper on NCT02955940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955940.